Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 131Astrocytoma 115Central Nervous System Neoplasms 110Melanoma 75Oligodendroglioma 74Neuroblastoma 44Neoplasms 33Medulloblastoma 33Neoplasm Metastasis 29Recurrence 28Ependymoma 26Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Small Cell Lung Carcinoma 16Lymphoma 16Carcinoma, Non-Small-Cell Lung 16Diffuse Intrinsic Pontine Glioma 15Lung Neoplasms 14Breast Neoplasms 14Ovarian Neoplasms 13Neuroendocrine Tumors 13Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Neuroectodermal Tumors, Primitive 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10

Interventions

Etoposide 3Carboplatin 2toripalimab 1tislelizumab 1fluzoparib 1atezolizumab 1Topotecan 1Temozolomide 1Radiotherapy 1PM 01183 1Drug Therapy 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
SCLC, Extensive Stage × Temozolomide × Clear all
NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
100 enrolled
Thoracic

SCLC, Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡